NEW YORK, NY — (Marketwire) — 11/18/09 — Vivakor, Inc. (OTCBB: VIVK) announced yesterday that its Board of Directors approved a dividend to share holders of record for December 1, 2009. Each shareholder will receive one (1) share of HealthAmerica, Inc. for every one (1) share of Vivakor, Inc. pending FINRA approval.

HealthAmerica, Inc. is in the process of developing a patented magnetic resonance imaging (MRI) image resolution enhancing technology called VIVASlices. With the sales of all medical devices slowing, a need for clearer more efficient machines is arising. With the decrease in sales of medical devices like MRIs, facilities are demanding more out of their machines and require them to produce better results.

It is estimated there are between 7,000 and 10,000 MRI machines in use in the United States alone. VIVASlices with its easy to use user interface will work on low, mid and high field magnets, opening

...

Nov. 17, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 17 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced that its Board of Directors approved a dividend of shares of common stock of HealthAmerica, Inc., a Nevada corporation of which Vivakor owns approximately 84% of the outstanding common stock. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on the record date. The record date for the distribution is expected to be December 1, 2009, subject to review and approval of FINRA, and the distribution date is expected to be December 9, 2009. After the dividend distribution, Vivakor will continue to own approximately 62% of the outstanding common stock of HealthAmerica.

Vivakor shareholders will not be required to take any action to receive the HealthAmerica common shares on the distribution date.

Vivakor Chairman Matt Nicosia

...

Microsemi Corporation’s (MSCC) fiscal fourth quarter earnings beat the consensus by a penny.

 The company reported revenue of $109.7 million, which was up 2.5% sequentially and down 18.6% year over year.   Microsemi’s Analog/Mixed Signal products cater to three end markets—mobile/connectivity, notebooks/LCD TVs/display and industrial/semicap.  The mobile/connectivity business (11% of revenue) grew 25.3% sequentially and declined 37.6% from the year-ago quarter. The business is currently being driven by the WLAN product line, as the high capital requirement of POE installations limit adoption in the current environment.  Notebooks/LCD TVs/displays generated 7% of revenue, representing a sequential increase of 43.5% and a year-over-year decline of 42.2%. The sequential strength in this business was driven by the seasonally strong LCD TV market, where Microsemi’s CCFL backlights gained share. This was partially offset by sluggish notebook CCFL and auto display markets.  The industrial/semicap business remains weak, generating just ...

Vivakor, Inc., a transdisciplinary research company that develops and acquires primarily biomedical and electro-optic products, has put together the contacts and technologies to establish a healthy position in what is estimated to be a $1.9 billion marketplace.

The company’s business model is to be a research hub focused on scientific and market needs that are not currently being met. Vivakor’s mission is to advance or acquire technologies that help patients, researchers, clinicians, and consumers, and the company realizes the importance of obtaining and coordinating the best scientific and business support to do this. To this end, it has established key relationships with various collaborative partners, and has developed strong product-specific commercialization strategies. Vivakor will have the necessary partnerships and licensing arrangements in place for each of its products from the very beginning of product conception or acquisition.

This approach has important advantages:

• More efficient research and development • Quicker time to market

...

Nov. 12, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 12 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) is the keynote presenting company at the founders’ celebration of consumer product specialist, Regeneca International, Inc. (www.regeneca.com). The celebration will be attended by over 200 founders and guests of Regeneca International from across the United States. It will be hosted at the prestigious Balboa Bay Club in Newport Beach, California. Vivakor’s Chairman, Matt Nicosia and CFO, Ed Corrente will both be attending the event.

Event attendee, Dr. Brian Scott , a Regeneca advisory board member and nationally recognized wellness expert, was particularly pleased to learn of Vivakor’s role in the event. “As a healthcare provider and speaker on issues regarding wellness and longevity, it is refreshing to hear the perspective of a company, doing business internationally, which can provide a particular focus on products which extend the length and

...

Protalix Biotherapeutics, Inc. continues to make headlines with its innovative compound, a recombinant form of glucocerebrosidase (prGCD). Last week, the company released that its compound had received the FDA’s Orphan Drug Donation. Yesterday, the company announced that they have completed the Phase III trial for prGCD. The compound is designed to treat Gaucher disease, a rare and serious lysosomal storage disorder in humans with debilitating symptoms.

Protalix plans to release top-line results from this study in October 2009, but has shed light on a few details; the trial enrolled 31 patients across Europe, North America, South America, Israel and South Africa. Most importantly, the company is pleased to report that no serious adverse events occurred in this trial. Protalix expects to complete its rolling New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) by the end of 2009.

The pivotal Phase III clinical trial of prGCD is a randomized,

...

Imaging3, Inc.

(Public, OTC:IMGG)

A new and radical medical device from Imaging3 Inc. (OTC:IMGG) is ready to set the standard, and revolutionize the way we look at X-ray, MRI and CT scans. Imaging 3 is currently awaiting FDA approval on their DViS (Dominion Volumetric Imaging Scanner). Currently, medical imaging is met with challenges of long waits, lack of space, lack of mobility, and limited uses. However, for the first time ever, health-care workers will be able to instantly view 3D, high-resolution images of virtually any part of the human body. Thus, Imaging 3 looks to change all that. Saving time, saving lives and reducing costs. This technology will “set the standard for the next 10 years.” The following article was composed by StocksHaven Investments alongside Professor Philip Runfeldt, a Behavioral Analyst who has worked with Fortune 500 companies and major Universities throughout

...

Power3 Medical Products, Inc.

(Public, OTC:PWRM)

The following company analysis has been contributed by a StocksHaven Investments affiliate and member, Michael Sklar. He has been studying the markets for several years now with a focus in undiscovered Bio-Pharm companies.

About

Power3 Medical Products, Inc. (Power3) is primarily engaged in commercializing its intellectual properties in the area of diagnosis and treatment of breast cancer, Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. In the area of neurodegenerative diseases and breast cancer, Power3 has completed research and clinical validation studies involving over 1,500 patient samples. Power3 uses biostatistical analysis to monitor appropriate panels of biomarkers for diagnostic sensitivity and specificity for disease, normal and disease controls. By testing patient body fluids and tissues, including blood serum (for breast cancer and neurodegenerative diseases), and bone marrow aspirates (for leukemia patients), the Company

...

Earlier this week, the US Food and Drug Administration (FDA) approved Novartis Pharma’s (NVS) Extavia, a branded version of interferon beta-1b, which is used for the treatment of multiple sclerosis (MS). Novartis obtained the rights to seek approval for its own branded version of interferon beta-1b through agreements signed with Bayer Schering, which markets Betaseron. MS is a chronic autoimmune disease in which the body's immune system attacks the myelin sheath, or protective tissue surrounding the nerve fibers that carry electrical signals in the brain. As a result, persons afflicted with the disease experience problems with muscle control and strength, vision, balance, sensation and mental function. Extavia has been approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. It is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with ...

Diagnostic Imaging International Corp. is focused on providing quality MRI services to its clients, delivering convenience, accuracy and a high standard of care and services. The company is committed to making available, on a timely basis, imaging services for individuals, physicians, workers compensation boards and insurance companies.

Security and privacy of health data transmissions are of the utmost importance. In order to ensure that these standards are being met, a high-level encryption system is in place along with an around-the-clock centralized command center.

Diagnostic Imaging International Corp. intends to continue its focus throughout the major metropolitan areas within North America by pursuing additional acquisitions of private diagnostic clinics. The vision of the company does not stop with its success in North America; its goal is to provide teleradiology services on a worldwide basis, which is projected to generate around $30 million dollars.

Let us hear your thoughts below: